EGFR and non-small cell lung carcinoma: EGFR is being targeted with the monoclonal antibodies cetuximab and panitumumab [12-17] and with two low molecular weight tyrosine kinase inhibitors, gefitinib and erlotinib [18-23] in several types of epithelial cancers, including head and neck, pancreatic, colorectal and a subset of non small cell lung cancers with mutant or highly expressed EGFR.